Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Antidepressant recalled: Second-highest FDA risk level
FDA Has Recalled Thousands of Bottles of Antidepressant Duloxetine, Sold Under Brand Name Cymbalta: Here’s Why
The U.S. Food and Drug Administration has recalled thousands of bottles of the antidepressant Duloxetine (sold under the brand name Cymbalta) for potentially cancer-causing chemicals in the medication.
7,100 bottles of antidepressant recalled by FDA now in 2nd highest risk class
Duloxetine Delayed-Release Capsules were recalled because the pills may contain high levels of a cancer-causing chemical.
Antidepressant recall: FDA upgrades medication risk class to 2nd highest level in recall update
The U.S. Food and Drug Administration is urging patients not to stop taking their prescribed medication if it falls under the recall but instead to address any concerns and other potential treatment o
Duloxetine antidepressant recalled over presence of toxic chemical
Some bottles of the antidepressant duloxetine, sold under the brand name Cymbalta, were recalled due to the presence of a toxic chemical.
FDA issues recall for antidepressant drug
The Federal Drug Administration issued a recall on Tuesday for a common medicine for depression. Over 7,000 bottles of Duloxetine were recalled due to the elevated presence of Nitrosamine, an ingredient believed to be cancerous,
Antidepressant recalled: 2nd-highest FDA risk level; drug contains cancerous chemical
The U.S. Food and Drug Administration updated the risk level of a recalled antidepressant due to the product containing high levels of a cancer-causing chemical.
FDA Recalls Thousands Of Duloxetine Antidepressant Bottles | Here's Why
The US Food and Drug Administration has recalled thousands of bottles of Duloxetine antidepressant, saying it contained high levels of a cancer-causing chemical. The federal agency has reportedly upgraded the level of risk.
Antidepressant recall: FDA upgrades risk level due to cancer-causing chemical
After the U.S. Food and Drug Administration recalled thousands of bottles of antidepressants it said contained high levels of a cancer-causing chemical, the federal agency has now upgraded the level of risk.
10h
on MSN
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
11h
on MSN
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...
STAT
8h
Novo asks FDA to bar compounders from making Ozempic copies
The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable ...
22h
US FDA declines to approve Camurus' rare hormone disorder drug
The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due ...
Convenience Store News
14h
FDA Seizes 3 Million Unauthorized E-Cigarettes in Joint Federal Operation
The Food and Drug Administration, in collaboration with the U.S. Customs and Border Protection (CBP), seized about three ...
STAT
14h
Michelle Tarver to lead FDA medical device center
Michelle Tarver will be the new leader of the medical devices center at the Food and Drug Administration, according to an ...
FierceBiotech
15h
Sangamo slashes time to market for Fabry gene therapy as FDA agrees to accelerated approval package
The biotech engaged with the FDA on alternative pathways to approval after seeing safety and efficacy data from the phase 1/2 ...
MassDevice
11h
iRhythm stock soars on FDA nod for changes to Zio AT following warning letter
Rhythm Technologies (Nasdaq:IRTC) announced today that it received FDA 510(k) clearance related to design changes made to its ...
BioPharma Dive
10h
FDA names Tarver as new head of device center
Michelle Tarver will officially replace longtime CDRH leader Jeff Shuren, who stepped down from the role earlier this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Pfizer
recall
United States
Food and Drug Administration
Duloxetine
Feedback